S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024

Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

$10.14
-0.33 (-3.15%)
(As of 04/12/2024 ET)

Phathom Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$21.33
110.39% Upside
High Forecast$28.00
Average Forecast$21.33
Low Forecast$10.00
TypeCurrent Forecast
4/14/23 to 4/13/24
1 Month Ago
3/15/23 to 3/14/24
3 Months Ago
1/14/23 to 1/14/24
1 Year Ago
4/14/22 to 4/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.33$21.33$23.00$20.17
Predicted Upside110.39% Upside87.63% Upside136.82% Upside146.09% Upside
Get Phathom Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.

PHAT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PHAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Phathom Pharmaceuticals Stock vs. The Competition

TypePhathom PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside110.39% Upside1,114.84% Upside10.14% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/11/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$26.00+120.34%
11/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00+10.99%
8/9/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Caufield
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$28.00+90.22%
5/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:55 AM ET.

PHAT Price Target - Frequently Asked Questions

What is Phathom Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Phathom Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for PHAT. The average twelve-month price prediction for Phathom Pharmaceuticals is $21.33 with a high price target of $28.00 and a low price target of $10.00. Learn more on PHAT's analyst rating history.

Do Wall Street analysts like Phathom Pharmaceuticals more than its competitors?

Analysts like Phathom Pharmaceuticals more than other Medical companies. The consensus rating score for Phathom Pharmaceuticals is 2.75 while the average consensus rating score for medical companies is 2.68. Learn more on how PHAT compares to other companies.

Does Phathom Pharmaceuticals's stock price have much upside?

According to analysts, Phathom Pharmaceuticals's stock has a predicted upside of 80.13% based on their 12-month stock forecasts.

What analysts cover Phathom Pharmaceuticals?

Phathom Pharmaceuticals has been rated by Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PHAT) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners